Arcutis Biotherapeutics, Inc. (ARQT) Tops Q1 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho
May 15, 2024 5:18 AM EDTMizuho analyst Uy Ear raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $18.00 (from $17.00) while maintaining a Buy rating.
The analyst comments "1Q24 was strong, with Zoryve (Cream + Foam) beating our above-Consensus forecasts driven by significantly better-than-expected gross-to-nets (GtN),... More



